66 results about "Gallocatechin" patented technology

A method and composition for preventing and treating Avian Influenza in Humans utilizes an effective quantity of polyphenolic(s) and/or its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid, (−)-epigallocatechin gallate (EGCG), (−) epigalloatechin (EGC), (+)-epicatechin (EC), (−)-gallocatechin gallate (GCG), and catechin.

The invention discloses a method for identifying the quality of Biluochun tea, which comprises the following steps of: after soaking the Biluochun tea, scanning the soaked solution by using an ultraviolet and visible spectrophotometer; and, after leaching and extracting another Biluochun tea, measuring the contents of epigallocatechin, epigallocatechin epicatechol gallate, epicatechin and epicatechin epicatechol gallate in the tea from the leached and extracted solution by adopting a high efficiency liquid chromatography. According to the method disclosed by the invention, a technology for identifying the quality of the Biluochun tea is established by adopting (a technology that spectrum and chromatograph are combined) spectrum and chromatograph analysis; the comprehensive evaluation data of green tea quality is provided; the method has the characteristics of being accurate, reliable, simple, convenient and efficient; and the method can be popularized and applied in the field of the green tea quality counterfeit identifying technology.

A method and composition for preventing and treating Avian Influenza utilizes an effective quantity of polyphenolic(s) and its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid, (−)-epigallocatechin gallate (EGCG), (−)epigalloatechin (EGC), (+)-epicatechin (EC), (−)-gallocatechin gallate (GCG), and catechin.

The invention described herein encompasses methods and compositions of preventing or treating cancer comprising the administration of a combination of therapeutically effective amount of catechins, a group of polyphenols found in green tea, and Capsicum extracts. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins and Capsicum extracts, in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds, including a formulation which may be used as a therapeutic compound for the treatment of cancer or as a dietary supplement for the prevention of cancer.

The invention discloses the application of epi-gallocatechin-gallate (EGCG) as a pig feed additive or in preparing the pig feed additive and the prepared pig feed, and particularly relates to the application of EGCG in preparing a feed additive for reducing the proportion of porcine skeletal muscle I type muscle fibers or reducing the proportion of red meat in porcine skeletal muscles. The invention shows that the EGCG is added to the pig feed , so that the proportion of skeletal muscle I type fibers can be reduced, the proportion of the red meat in the porcine skeletal muscles can be reduced, and the health of meat products can be improved. In addition, the pig feed added with the EGCG is a safe feed, and the pig feed does not contain substances which are toxic and harmful to the growth and the health of pigs; the addition amount of the EGCG is small, the EGCG can be directly added to a premix, and the addition process is convenient and swift; the preparation method is simple, requirements for special equipment do not exist, and the EGCG has good popularization and application prospects.

The invention discloses an application of various compounds such as polyphenols in resisting coronavirus. The invention relates to the application of one or more of a polyphenol substance, a proton pump inhibitor, p-benzoquinone and a derivative thereof, an active ingredient of sappan wood, TDZD-8, thiomersalate, alkannin, Tidelusib, protoflavin, rabeprazole sodium, PX-12, Dixanthophygen, methyl cholate, carbamofluorine, corilagin, dihydromyricetin, chloramine T, merbromin, gallocatechin, fraxetin, meisoindigo, a lactic acid ethacridine monohydrate and sousoprazole in preparation of drugs for treating and/or preventing diseases caused by coronavirus. In-vitro enzyme activity experiments show that various compounds such as 1, 4-naphthoquinone and the like can well inhibit the activity of main protease in the coronavirus, and the defect that diseases caused by the coronavirus cannot be treated in the prior art is overcome.

The invention discloses an application of gallocatechin in the preparation of drugs for resisting benign prostatic hyperplasia. According to the invention, through a prostatic hyperplasia model in ovariectomized rats induced by testosterone propionate, gallocatechin is selected as a therapeutic drug so as to observe the influence on rat prostate weight and index and pathological changes of prostate tissues. Research results show that gallocatechin can significantly reduce the prostate weight and prostate index of the animal model and improve pathological symptoms of prostate tissues.

The invention discloses a fat-soluble gallocatechin gallate palmitate and alcohol compound disinfectant and a preparation method thereof, which are prepared by mixing an organic solution and an inorganic solution. Organic solution contains glycerin, alcohol, vitamin E, fat-soluble gallocatechin gallate palmitate. The inorganic solution contains ion-free water, gel polymer, surfactant, aloe vera extract, and acid-base regulator. Steps: 1. Prepare an organic solution: add fat-soluble gallocatechin gallate palmitate, alcohol and auxiliary materials and mix uniformly to obtain an organic solution. 2. Prepare inorganic solution: polyquaternium-10, benzalkonium chloride, cetyltrimethylammonium chloride, carbomer Ultrez 20, and aloe vera extract dissolved in deionized water. 3. Add the organic solution to the inorganic solution to obtain a disinfectant. The formula is reasonable and easy to use. Long-acting, efficient, non-toxic, anti-oxidant. It does not contain pollutants and toxic substances, and is suitable for disinfection of human skin surfaces and object surfaces.

The invention belongs to the field of medicines or health products, and particularly relates to the use of catechin and epicatechin compounds in the preparation of drugs for up-regulating the expression level of microRNA-126. As found by researches, catechin, catechin gallate, gallocatechin, (-)-gallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallatecan up-regulate the expression level of the microRNA-126, and can be used for treating tumors, asthma, inflammatory bowel disease, vascular inflammation, hypertension, type 2 diabetes mellitus, diabetic nephropathy or diabetic retinopathy.

Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone. Also provided are nanoformulations based on nanoparticles with one or more anti-cancer agents and/or one or more modulators for preventing and/or treating neoplasms.

The invention discloses a ginkgo GbFLSa gene and an expression protein and application thereof, and belongs to the technical field of plant genetic engineering. The nucleotide sequence of the ginkgo GbFLSa gene is as shown in SEQID No.1, and the amino acid sequence of the expression protein is SEQID No.3. The ginkgo GbFLSa gene is subjected to transgenosis into Populus davidiana x P.bolleana, theinventor finds that the content of proanthocyanidins including catechin, epicatechin, epigallocatechin, gallocatechin and the like in transgenic poplar is notably reduced, and in addition, the expression level of DFR, ANS and LAR enzyme genes is also notably lower than that of the control group, which indicates that GbFLSa coding protein is a functional protein, and has the effect of negative adjustment and control on biologic synthesis of the proanthocyanidins. Disclosure of the effect of the GbFLSa to plant metabolism is facilitated, and the potential molecular mechanism of flavonoid biologic synthesis can be better known.

Disclosed herein is a nanoparticle composition comprising nanoparticles formed from one of: a conjugate of dimeric epigallocatechin-3-O-gallate and hyaluronic acid; a conjugate of epigallocatechin-3-O-gallate and hyaluronic acid; or a epigallocatechin-3-O-gallate-terminated hyaluronic acid conjugate; and an active agent or a pharmaceutically acceptable salt, solvate or prodrug thereof suitable to treat acute myeloid leukaemia, wherein the active agent is encapsulated in the nanoparticles.

The invention discloses a multi-component content determination method of Miao medicine Laportea bulbifera. The method comprises the following steps: S100, preparation of mixed reference solution, respectively and accurately weighing right amount of reference substances of Gallocatechin, neochlorogenic acid, Epigallocatechin, catechinic acid, chlorogenic acid, Cyclohexanecarboxylic acid, epicatechin, rutin, isoquercitrin, kaempferol-3-0-rutinoside and quercitrin; and simultaneously determining contents of eleven components including the Gallocatechin, the neochlorogenic acid, the Epigallocatechin, the catechinic acid, the chlorogenic acid, the Cyclohexanecarboxylic acid, the epicatechin, the rutin, the isoquercitrin, the kaempferol-3-0-rutinoside and the quercitrin. The method is simple, efficient, highly sensitive and excellent in specificity, and can provide baisis for quality control of Laportea bulbifera medicinal materials. Compared with the ordinary liquid phase, the method has the advantages of being accurate, reliable and highly sensitive, and having lower specificity detection limit and quantification limit, and is more effective in medicinal material component content analysis through a liquid chromatography-mass spectrometry analysis technology.

The invention belongs to the fields of medicines and gene engineering and provides a medicinal composition capable of inhibiting proliferation of tumor cells. The medicinal composition comprises gallocatechin epicatechol gallate and doxorubicine which serve as active ingredients and necessary pharmaceutical auxiliary materials, wherein the molar ratio of the gallocatechin epicatechol gallate to the doxorubicine is (400:1) to (20:1). Tests prove that the composition prepared from the gallocatechin epicatechol gallate and the doxorubicine, or prepared by combining the doxorubicine with the gallocatechin epicatechol gallate can obviously improve the curative effect of the doxorubicine of inhibiting proliferation of the tumor cells. The medicinal composition basically does not have toxicity to livers and kidneys of nude mice; and the gallocatechin epicatechol gallate in the active ingredients is rich in resources and low in price, so the tumor inhibition ratio is increased and the treatment cost of tumor patients is reduced.

The invention discloses a high-stability pigment derivative, and the number-average molecular weight of the pigment derivative is 523-168Da. In the structural unit, the content of epicatechin is 5-30%, the content of catechin is 3-75%, the content of gallocatechin is 1-13%, the content of epigallocatechin is 1-5%, the content of catechin gallate is 1-16%, and the content of epicatechin gallate is2-17%. The pigment derivative provided by the invention belongs to a natural anthocyanin derivative, is not influenced by the chemical balance of salt, chalcone, Quinoid alkali and methanol pseudo-base, can keep stable red in an acidic to neutral (pH 1.0-7.0) solution, and is not influenced by pH, oxygen, a reduced bleaching agent and temperature. The problem of poor color stability of natural anthocyanin is solved.

The invention discloses gallocatechin and gallocatechin in preparing an intestinal pathogenic bacterium medicine and a feed additive. The intestinal pathogenic bacterium medicine and the feed additivewhich are prepared from the gallocatechin as a raw material are derivatives prepared by taking the gallocatechin as a framework, and targeted intestinal pathogenic bacteria are enterotoxin productionescherichia coli K88, K99 and 987P. Research of multiple methods verifies that the gallocatechin has a very good antibacterial effect on intestinal pathogenic bacteria; and at a cell level, the gallocatechin is verified as being nontoxic, odor-free, nonirritant for bodies and free of mutagenesis, carcinogenesis or teratogenesis. As a natural extract, the gallocatechin is widely applied to aspectsof natural food preservatives, makes a security basis for animal use, provides candidate substances for development of novel anti-intestinal pathogenic bacterium medicines and substitutes of antibiotics and has very good application prospects in prevention and treatment on intestinal pathogenic bacteria.

The invention relates to a preparation method and application of hydroxyl cinnamyl ester type catechins. The hydroxyl cinnamyl ester type catechins comprise four catechins which are respectively namedas epicatechin trans-coumarate, epicatechin trans-caffeic acid ester, epigallocatechin trans-coumarate and epigallocatechin trans-caffeic acid ester. The hydroxyl cinnamyl ester type catechins are prepared by the following steps: carrying out four steps of full acetylation on epicatechin and epigallocatechin, removal of acetyl on phenolic hydroxyl, silanizing of phenolic hydroxyl and removal of 3-acetyl, then respectively esterifying with acetylated caffeic acid or coumaric acid acyl chloride, and removing a protecting group. The preparation method of the four catechins is simple and mild inconditions, and can be completed under general experimental conditions. The four hydroxycinnamyl ester type catechins have a certain inhibition effect on the activity of alpha-glucosidase, can be usedfor hypoglycemic drugs, and have important significance in the fields of agriculture and medicine.

The invention discloses a preparation process of high-linoleic-acid antioxidant powdered oil, and belongs to the technical field of functional powdered oil processing. The process comprises the following specific steps: (1) mixing a soybean protein isolate solution with a glucan solution, and performing freeze-drying to obtain glycated protein; (2) mixing the glycated protein solution with a gallocatechin solution and a conjugated linoleic acid solution, and carrying out high-speed shearing emulsification treatment; (3) performing jet cavitation treatment on the mixed emulsion to obtain a nano-emulsion; and (4) performing microwave constant-temperature convection drying on the nano-emulsion to obtain the high-linoleic-acid antioxidant powdered oil. According to the process, jet cavitationand microwave constant-temperature convection drying technologies are combined to prepare the high-linoleic-acid antioxidant powdered oil, and the powdered oil produced by the process is good in sensory quality, high in linoleic acid content and high in oxidation resistance, and has a wide application prospect.

The invention provides application of catechin to preparation of an animal feed additive and feed, the catechin is one or more of epigallocatechin gallate, epigallocatechin, epicatechin and epicatechin gallic acid, and the catechin is applied to preparation of the feed additive for improving the physique of newborn animals. When the catechin animal feed additive is applied to prepare a catechin feed, the addition amount of catechin is 0.05-20% based on the total mass of the feed, nutrient element absorption of a parent body is increased, nutrient element absorption of a daughter in the parent body and formation of an immune system are promoted, nutrient element storage of the daughter is increased, the physique of a newborn animal is improved, the weight of the newborn animal is increased, and the survival rate of the newborn animal is increased. The survival rate of newborn animals is improved.

Bacterial vaginosis is treated using methods and compositions that include one or more plant polyphenols as active ingredients. Preferred routes of administration of contemplated plant polyphenols include topical and oral administration, and particularly preferred plant polyphenols are prepared from green tea (e.g., Polyphenon E) and/or may include (−)-epigallocatechin gallate, (−)-epicatechin gallate, (−)-epigallocatechin, and (−)-epicatechin.

This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer.

The invention belongs to the field of medicines or health products, and particularly relates to the use of catechin and epicatechin compounds in the preparation of drugs for up-regulating the expression level of microRNA-150. As found by researches, catechin, catechin gallate, gallocatechin, (-)-gallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallatecan up-regulate the expression level of the microRNA-150, and can be used for treating myocardial hypertrophy, hypertension, ischemic cardiomyopathy, myocardial infarction, arrhythmia, cancer or sepsis.

The invention relates to functional food/drink with antiallergic actions, which contain one or more selected from the group consisting of epigallocatechin-3-O-(3-O-methyl)gallate and gallocatechin-3-O-(3-O-methyl)gallate, epigallocatechin-4-O-(4-O-methyl)gallate and gallocatechin-4-O-(4-O-methyl)gallate, and strychnine.